company background image

Biotest XTRA:BIO3 Stock Report

Last Price


Market Cap







01 Jun, 2023


Company Financials +

BIO3 Stock Overview

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally.

BIO3 fundamental analysis
Snowflake Score
Future Growth4/6
Past Performance0/6
Financial Health1/6

My Notes

Capture your thoughts, links and company narrative

Biotest Aktiengesellschaft Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biotest
Historical stock prices
Current Share Price€31.60
52 Week High€36.40
52 Week Low€29.60
1 Month Change-0.63%
3 Month Change-5.67%
1 Year Change-11.73%
3 Year Change55.67%
5 Year Change26.15%
Change since IPO401.40%

Recent News & Updates

Recent updates

Shareholder Returns

BIO3DE BiotechsDE Market

Return vs Industry: BIO3 underperformed the German Biotechs industry which returned -4.6% over the past year.

Return vs Market: BIO3 underperformed the German Market which returned -8.5% over the past year.

Price Volatility

Is BIO3's price volatile compared to industry and market?
BIO3 volatility
BIO3 Average Weekly Movement3.4%
Biotechs Industry Average Movement6.7%
Market Average Movement5.0%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.7%

Stable Share Price: BIO3 is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: BIO3's weekly volatility (3%) has been stable over the past year.

About the Company

19462,228Michael Ramroth

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas.

Biotest Aktiengesellschaft Fundamentals Summary

How do Biotest's earnings and revenue compare to its market cap?
BIO3 fundamental statistics
Market Cap€1.46b
Earnings (TTM)-€47.20m
Revenue (TTM)€517.40m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BIO3 income statement (TTM)
Cost of Revenue€394.00m
Gross Profit€123.40m
Other Expenses€170.60m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 10, 2023

Earnings per share (EPS)-1.19
Gross Margin23.85%
Net Profit Margin-9.12%
Debt/Equity Ratio185.4%

How did BIO3 perform over the long term?

See historical performance and comparison